Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New daily pill shows promise for Hard-to-Treat leukemia

NCT ID NCT06163430

Disease control Sponsor: Terns, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new daily pill called TERN-701 for adults with chronic myeloid leukemia (CML) who have not responded well to other treatments. The trial has two parts: first, finding the safest dose, then testing that dose in more people. About 180 participants will take the pill once a day in 28-day cycles, and researchers will monitor safety and how well it controls the cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TERN-701 (a daily pill that targets a specific protein in cancer cells)
What this could lead to
If successful, this could offer a new daily treatment option for people with chronic myeloid leukemia who have not responded well to other therapies.
What could go wrong
This is an early-phase trial, so the drug may not work as hoped or could cause unexpected side effects. It is also not a cure—patients will likely need to take it long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Male or female participants ≥ 18 years of age at the time of signing the informed consent * Have an ECOG performance status score of 0 to 2 * Have an established cytopathologically confirmed diagnosis of BCR-ABL1 positive CML in Chronic Phase * Have received treatment with at least one prior TKI and have treatment failure, suboptimal response, or treatment intolerance * Prior treatment with asciminib is allowed * Adequate organ function, as assessed by local laboratory Key Exclusion Criteria: * Systemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of TERN-701 * Have completed previous anticancer therapy without resolution of all associated clinically significant toxicity (to ≤ Grade 2 or baseline)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid, Chronic-Phase

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic myeloid leukemia Chronic myeloid leukemia, chronic phase

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    54 sites in 9 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Atrium Health Levine Cancer Institute

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

  • Auckland City Hospital

    NOT_YET_RECRUITING

    Auckland, 1023, New Zealand

  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola

    RECRUITING

    Bologna, 40138, Italy

  • Banner MD Anderson Cancer Center

    RECRUITING

    Gilbert, Arizona, 85234, United States

  • CHU de Nantes (University Hospital of Nantes) - Hôtel Dieu

    RECRUITING

    Nantes, 44093, France

  • Centre Hospitalier Lyon-Sud

    RECRUITING

    Pierre-Bénite, 69495, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, Auvergne-Rhône-Alpes, 69008, France

  • Charité Campus Virchow-Klinikum - Universitätsmedizin Berlin

    RECRUITING

    Berlin, 10117, Germany

  • Christchurch Hospital

    RECRUITING

    Christchurch, 8011, New Zealand

  • Dong-A University hospital

    RECRUITING

    Busan, 49201, South Korea

  • Florida Cancer Affiliates - Ocala

    RECRUITING

    Ocala, Florida, 34474, United States

  • Florida Cancer Specialists - East Region Research Office

    NOT_YET_RECRUITING

    West Palm Beach, Florida, 33401, United States

  • Florida Cancer Specialists - North Region Research Office

    NOT_YET_RECRUITING

    St. Petersburg, Florida, 33705, United States

  • Florida Cancer Specialists - South Region Research Office

    NOT_YET_RECRUITING

    Fort Myers, Florida, 33901, United States

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    RECRUITING

    Milan, 20122, Italy

  • Fondazione IRCCS San Gerardo dei Tintori

    RECRUITING

    Monza, 20900, Italy

  • Fondazione IRCCS San Gerardo dei Tintori - SC Centro di Ricerca Fase I

    RECRUITING

    Monza, 20900, Italy

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • Georgia Cancer Center at Augusta University

    RECRUITING

    Augusta, Georgia, 30912, United States

  • Hallym University Sacred Heart Hospital

    RECRUITING

    Anyang-si, Gyeonggido, 14068, South Korea

  • Hospital Clínic de Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital Universitari Germans Trias i Pujol (ICO Badalona)

    RECRUITING

    Barcelona, 08916, Spain

  • Hospital Universitari Vall d'Hebrón

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Ramón y Cajal

    RECRUITING

    Madrid, 28034, Spain

  • Hospital Universitario de Gran Canaria Doctor Negrín

    RECRUITING

    Las Palmas, 35010, Spain

  • Hospital Universitario de La Princesa

    RECRUITING

    Madrid, 28006, Spain

  • Hospital de Día Quirónsalud Zaragoza

    RECRUITING

    Zaragoza, 50012, Spain

  • Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Hôpital Saint Louis

    RECRUITING

    Paris, 75010, France

  • Imperial College Healthcare NHS Trust

    RECRUITING

    London, England, W12 0HS, United Kingdom

  • Institut Bergonié

    RECRUITING

    Bordeaux, 33076, France

  • Institut Paoli Calmettes

    RECRUITING

    Marseille, 13273, France

  • Keimyung University Dongsan Hospital

    RECRUITING

    Daegu, 42601, South Korea

  • Klinikum rechts der lsar der Technischen Universität München

    RECRUITING

    München, 81675, Germany

  • Medizinische Hochschule Hannover

    RECRUITING

    Hanover, 30625, Germany

  • Memorial Sloan Kettering Cancer Center - Main Campus

    RECRUITING

    New York, New York, 10065, United States

  • Monash Medical Centre

    NOT_YET_RECRUITING

    Clayton, Victoria, 3168, Australia

  • Oregon Health & Science University

    RECRUITING

    Portland, Oregon, 97239, United States

  • Peter MacCallum Cancer Centre

    NOT_YET_RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Rocky Mountain Cancer Centers, LLP

    RECRUITING

    Lone Tree, Colorado, 80303, United States

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Royal Perth Hospital

    RECRUITING

    Perth, Western Australia, 6000, Australia

  • The University of Texas M.D. Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Thomas Jefferson University - Center City (Philadelphia)

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • Tristar BMT

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • UC Irvine Health

    RECRUITING

    Orange, California, 92868, United States

  • Uijeorigbu Eulji Medical Center, Eulji University

    RECRUITING

    Uijeongbu-si, Gyeonggi-do, 11749, South Korea

  • University of Alabama Medicine (UAB Medicine)

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • Universitätsklinikum Aachen

    RECRUITING

    Aachen, 52074, Germany

  • Universitätsklinikum Frankfurt

    RECRUITING

    Frankfurt am Main, 60590, Germany

  • Universitätsklinikum Jena

    RECRUITING

    Jena, 07747, Germany

  • Universitätsklinikum Mannheim

    RECRUITING

    Mannheim, 68167, Germany

  • Willamette Valley Cancer Institute and Research Center

    RECRUITING

    Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.